Neurology

Article	Citations
Neurologic manifestations in hospitalized patients with COVID-19	583
Miller Fisher syndrome and polyneuritis cranialis in COVID-19	566
Research criteria for the diagnosis of prodromal dementia with Lewy bodies	353
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions	318
Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19	291
International Consensus Guidance for Management of Myasthenia Gravis	261
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis	259
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy	247
COVID-19 presenting with ophthalmoparesis from cranial nerve palsy	225
Twenty-seven-year time trends in dementia incidence in Europe and the United States	221
COVID-19 and neuromuscular disorders	213
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy	204
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	194
Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid	185
Early postmortem brain MRI findings in COVID-19 non-survivors	184
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy	170
Neurologic and neuroimaging findings in patients with COVID-19	169
Global prevalence and burden of HIV-associated neurocognitive disorder	163
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis	155
Frequency of Neurologic Manifestations in COVID-19	148
Neurologic complications of coronavirus infections	147
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic	145
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome	145
Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder	140
Different phenotypes in dermatomyositis associated with anti-MDA5 antibody	139

Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI	133
Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection	132
COVID-19 is catalyzing the adoption of teleneurology	128
Neurofilament light as a biomarker in traumatic brain injury	125
Incidence and Prevalence of Drug-Resistant Epilepsy	124
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies	123
New onset neurologic events in people with COVID-19 in 3 regions in China	121
Healthy lifestyle and the risk of Alzheimer dementia	120
Long-Haul COVID	120
Bilateral transient olfactory bulb edema during COVID-19–related anosmia	118
Practice advisory update summary: Patent foramen ovale and secondary stroke prevention	117
Global, Regional, and National Burden of Ischemic Stroke, 1990–2019	116
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS	116
Keeping people with epilepsy safe during the COVID-19 pandemic	111
Dietary flavonols and risk of Alzheimer dementia	109
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures	108
Neurologic Adverse Events of Immune Checkpoint Inhibitors	107
Rapid implementation of virtual neurology in response to the COVID-19 pandemic	107
Neurologic manifestations in an infant with COVID-19	104
Analyzing 2,589 child neurology telehealth encounters necessitated by the COVID-19 pandemic	103
Serum neurofilament light as a biomarker in progressive multiple sclerosis	102
Criteria for defining interictal epileptiform discharges in EEG	99
Generalized myoclonus in COVID-19	99
Total Aβ 42 /Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis	99
Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline	99
Scoping review of prevalence of neurologic comorbidities in patients hospitalized for COVID-19	99
Secondary Progressive Multiple Sclerosis	99
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies	98
Brain arteriovenous malformations	95
Long-term safety, tolerability, and efficacy of fremanezumab in migraine	95
ATN classification and clinical progression in subjective cognitive decline	95
Stroke risk, phenotypes, and death in COVID-19	94
Neurologic autoimmunity and immune checkpoint inhibitors	93
Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease	92
Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies	91
Association of epileptiform abnormalities and seizures in Alzheimer disease	91
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis	90
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease	89
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques	88
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease	88
Sex-driven modifiers of Alzheimer risk	87
Determination of death by neurologic criteria around the world	87
Loss of smell in patients with COVID-19	86
Intracranial hemodynamic relationships in patients with cerebral small vessel disease	85
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis	84
Initial high-efficacy disease-modifying therapy in multiple sclerosis	83
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke	82
Five years of ocrelizumab in relapsing multiple sclerosis	82
Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy	82
Cranial neuropathies and COVID-19	81

Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial	81
Worldwide Incidence and Prevalence of Neuromyelitis Optica	81
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease	81
Incidence and case fatality rate of COVID-19 in patients with active epilepsy	80
Exosomal neurofilament light	80
Thrombus NET content is associated with clinical outcome in stroke and myocardial infarction	80
Pearls & Oy-sters: Facial nerve palsy in COVID-19 infection	78
Tobacco smoking and the risk of Parkinson disease	78
Aerobic exercise improves cognition and cerebrovascular regulation in older adults	78
Preserving stroke care during the COVID-19 pandemic	77
The implications of different approaches to define AT(N) in Alzheimer disease	77
Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders	77
Probiotics for Constipation in Parkinson Disease	77
Mortality in patients with psychogenic nonepileptic seizures	74
Deep brain stimulation in early-stage Parkinson disease	74
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis	74
NfL as a biomarker for neurodegeneration and survival in Parkinson disease	73
Diagnosis of prion diseases by RT-QuIC results in improved surveillance	72
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality	72
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET	72
The 2013 clinical course descriptors for multiple sclerosis	71
Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease	71
Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort	70
Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age	69
Astrocyte Biomarkers in Alzheimer Disease	69
Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis	68
Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease	68
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms	68
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19	68
Effect of ApoE isoforms on mitochondria in Alzheimer disease	68
In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease	68
Severe childhood speech disorder	67
Long-term exposure to air pollution and trajectories of cognitive decline among older adults	67
Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease	66
Telephone-based cognitive behavioral therapy for depression in Parkinson disease	66
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program	66
Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study	65
Evaluation of efficacy and tolerability of first-line therapies in NMOSD	65
Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19	65
On being a neurologist in Italy at the time of the COVID-19 outbreak	64
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis	63
The Economic Burden of Multiple Sclerosis in the United States	63
Life Expectancy in Duchenne Muscular Dystrophy	63
Noncontrast CT markers of intracerebral hemorrhage expansion and poor outcome	62
Cardiovascular risk factors and accelerated cognitive decline in midlife	62
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light	62
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary	62
Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis	61
In Vivo Diagnosis of Synucleinopathies	61
Serum triglycerides in Alzheimer disease	60
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation	60
Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder	60
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays	60
Identification of GGC repeat expansion in the NOTCH2NLC gene in amyotrophic lateral sclerosis	59
Glial Fibrillary Acidic Protein Autoimmunity	59
Real-life gait assessment in degenerative cerebellar ataxia	59
Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes	59
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies	58
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease	58
Ketamine to treat super-refractory status epilepticus	58
Prevalence and Significance of Impaired Microvascular Tissue Reperfusion Despite Macrovascular Angiographic Reperfusion (No-Reflow)	58
Associations of Social Isolation and Loneliness With Later Dementia	58
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis	58
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder	58
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary	57
Minor neuropsychological deficits in patients with subjective cognitive decline	56
Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA	56
Blood biomarkers of traumatic brain injury and cognitive impairment in older veterans	56
In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment	56
Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease	55
Natalizumab in acute ischemic stroke (ACTION II)	55
Temporal Dynamics of β-Amyloid Accumulation in Aging and Alzheimer Disease	55
Multitracer model for staging cortical amyloid deposition using PET imaging	55
Multicenter prospective study on predictors of short-term outcome in disorders of consciousness	55
Population-based analysis of survival in spinal muscular atrophy	54
Indications for Mechanical Thrombectomy for Acute Ischemic Stroke	54
Association of Dilated Perivascular Spaces With Cognitive Decline and Incident Dementia	54
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis	54
COVID-19–related encephalopathy responsive to high-dose glucocorticoids	54
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease	54

Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy	54
Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States	54
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs	53
Detecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults	53
Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis	53
Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies	53
Effects of home-based telerehabilitation in patients with stroke	53
Thalamus and focal to bilateral seizures	53
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years	52
Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis	52
Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study	52
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies	52
Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration	52
Applying Propensity Score Methods in Clinical Research in Neurology	52
Risk of Stroke in Cancer Survivors	51
Association of Collateral Status and Ischemic Core Growth in Patients With Acute Ischemic Stroke	51
Long-term Dietary Flavonoid Intake and Subjective Cognitive Decline in US Men and Women	51
Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy	51
Prognostic value of diffusion-weighted MRI for post-cardiac arrest coma	50
The Ictal Signature of Thalamus and Basal Ganglia in Focal Epilepsy	50
Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction	50
Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease	50
Central effects of erenumab in migraine patients	49
Broad phenotype of cysteine-altering NOTCH3 variants in UK Biobank	49
Functional gait disorders	49
Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration	49
Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease	49
Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults	49
Bi-directional association between epilepsy and dementia	49
Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease	48
Modeling disease trajectory in Duchenne muscular dystrophy	48
Association of Cerebral Small Vessel Disease and Cognitive Decline After Intracerebral Hemorrhage	48
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis	47
Pharmacologic treatment and SUDEP risk	47
Neurogenic Dysphagia	47
Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging	47
Longitudinal white-matter abnormalities in sports-related concussion	46
Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods	46
Sleep, major depressive disorder, and Alzheimer disease	46
Association of Loneliness With 10-Year Dementia Risk and Early Markers of Vulnerability for Neurocognitive Decline	46
Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis	46
Diffusion-weighted MRI in transient global amnesia and its diagnostic implications	46
Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN Registry	46
Idiopathic distal sensory polyneuropathy	46
Association of Age at Onset and First Symptoms With Disease Progression in Patients With Metachromatic Leukodystrophy	46
Racial and Ethnic Disparities in Multiple Sclerosis Prevalence	46
Preparing a neurology department for SARS-CoV-2 (COVID-19)	46
Characterizing opioid use in a US population with migraine	46
Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia	46
Dementia in late-onset epilepsy	46
Diet pattern and prodromal features of Parkinson disease	45
Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ε4 genotype	45
Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution	45
Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension	45
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies	45
Sleep disorders in anti-NMDAR encephalitis	45
GBA variants in REM sleep behavior disorder	45
DNA Methylation and Protein Markers of Chronic Inflammation and Their Associations With Brain and Cognitive Aging	45
Neurologic deterioration in patients with acute ischemic stroke or transient ischemic attack	45
The clinical, histologic, and genotypic spectrum of SEPN1 -related myopathy	44
Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum	44
Cerebral Amyloid Angiopathy–Related Transient Focal Neurologic Episodes	44
Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines	44
7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice	44
Seeing ophthalmologic problems in Parkinson disease	44
A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS	44
Association of initial imaging modality and futile recanalization after thrombectomy	44
Autoimmune Encephalitis After SARS-CoV-2 Infection	43
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory	43
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors	43
Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation	43
Intravenous Immunoglobulin Therapy in Patients With Painful Idiopathic Small Fiber Neuropathy	43
Vitamin D, smoking, EBV, and long-term cognitive performance in MS	43
Association of Sleep, Neuropsychological Performance, and Gray Matter Volume With Glymphatic Function in Community-Dwelling Older Adults	43
Cell Therapy for Chronic TBI	42
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy	42
Acute symptomatic seizures in cerebral venous thrombosis	42
Dystonia and Tremor	42
A Shortage of Neurologists – We Must Act Now	41
Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies	41
Abnormal development of cerebellar-striatal circuitry in Huntington disease	41
Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis	41
Blood Pressure After Endovascular Thrombectomy and Outcomes in Patients With Acute Ischemic Stroke	41
Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990–2030	41
Analysis of the association of MPO and MMP-9 with stroke severity and outcome	41
Progression to Dementia or Reversion to Normal Cognition in Mild Cognitive Impairment as a Function of Late-Onset Neuropsychiatric Symptoms	41
Association of common genetic variants with brain microbleeds	41
Safety and efficacy of remote ischemic postconditioning after thrombolysis in patients with stroke	41
One-year sustained efficacy of erenumab in episodic migraine	41
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease	40
Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis	40
Incidence, Prevalence, and Health Care Outcomes in Idiopathic Intracranial Hypertension	40
Prevention of benign paroxysmal positional vertigo with vitamin D supplementation	40
Location-specific risk factors for intracerebral hemorrhage	40
Risk factors of Parkinson disease	40